Skip to main content
Advertisement
Advertisement
INCY
INCY logo
Incyte Genomics Inc
120.27
USD
Sponsored
-0.70
-0.58%
Nov 16, 15:59 UTC -5
Closed
exchange

After-Market

120.52

+0.25
+0.20%

Incyte Genomics Inc (INCY) Earnings

INCY Earnings Reports

Positive Surprise Ratio

INCY beat 23 of 43 last estimates.

53%

Next Report

Date of Next Report
Feb 08, 2027
Estimate for Q4 26 (Revenue/ EPS)
$1.58B
/
$2.02
Implied change from Q3 26 (Revenue/ EPS)
+1.61%
/
-156.11%
Implied change from Q4 25 (Revenue/ EPS)
+5.00%
/
+12.22%

Incyte Genomics Inc earnings per share and revenue

On Oct 29, 2026, INCY reported earnings of -3.60 USD per share (EPS) for Q3 26, beating the estimate of -3.92 USD, resulting in a 8.33% surprise. Revenue reached 1.56 billion, compared to an expected 1.49 billion, with a 4.18% difference. The market reacted with a -0.06% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of 2.02 USD, with revenue projected to reach 1.58 billion USD, implying an decrease of -156.11% EPS, and increase of 1.61% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Enanta Pharmaceuticals, Inc
Report Date
Nov 16, 2026 For Q4 26
Estimate
-$0.79
Actual
-$0.81
Surprise
-1.38%
logo
Genelux Corporation Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.22%
logo
Neumora Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.20
Actual
-$0.18
Surprise
+10.54%
logo
Eloxx Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.58
Actual
-$0.49
Surprise
+16.70%
logo
Rein Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
logo
Connect Biopharma Holdings Limited Ordinary Shares
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+4.59%
logo
Instil Bio, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.17
Actual
-$0.62
Surprise
-261.09%
logo
Estrella Immunopharma, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.17
Surprise
-108.33%
logo
Jasper Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.02
Actual
-$13.97
Surprise
-361.93%
logo
Kyntra Bio, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.61
Actual
-$3.42
Surprise
+5.49%
FAQ
For Q3 2026, Incyte Genomics Inc reported EPS of -$3.60, beating estimates by 8.33%, and revenue of $1.56B, 4.18% above expectations.
The stock price moved down -0.06%, changed from $116.87 before the earnings release to $116.80 the day after.
The next earning report is scheduled for Feb 08, 2027.
Based on -- analysts, Incyte Genomics Inc is expected to report EPS of $2.02 and revenue of $1.58B for Q4 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement